Overexpression of Cyclooxygenase-1 Correlates with Poor Prognosis in Renal Cell Carcinoma |
Yu, Zu-Hu
(Department of Urology, Peking University Shenzhen Hospital)
Zhang, Qiang (Department of Urology, Peking University Shenzhen Hospital) Wang, Ya-Dong (Department of Urology, Peking University Shenzhen Hospital) Chen, Jing (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Jiang, Zhi-Mao (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Shi, Min (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Guo, Xin (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Qin, Jie (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Cui, Guang-Hui (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Cai, Zhi-Ming (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Gui, Yao-Ting (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) Lai, Yong-Qing (Department of Urology, Peking University Shenzhen Hospital) |
1 | Amin MB, Tamboli P, Javidan J, et al (2002). Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol, 26, 281-91. DOI ScienceOn |
2 | Bao S, Ouyang G, Bai X, et al (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 5, 329-39. DOI ScienceOn |
3 | Choi YD, Kim KS, Ryu S, et al (2007). Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci, 22, 305-10. DOI ScienceOn |
4 | Daikoku T, Wang D, Tranguch S, et al (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res, 65, 3735-44. DOI ScienceOn |
5 | Diamantopoulou K, Lazaris A, Mylona E, et al (2005). Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Anticancer Res, 25, 4543-9. |
6 | Greene F BC, Fleming I, Fritz A, Haller D. 2002. AJCC: Cancer Staging Manual. New York: Springers-Verlag. |
7 | Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11. |
8 | Hashimoto Y, Kondo Y, Kimura G, et al (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology, 44, 353-9. DOI ScienceOn |
9 | Hida T, Yatabe Y, Achiwa H, et al (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res, 58, 3761-4. |
10 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300. DOI |
11 | Jiang Z, Chu PG, Woda BA, et al (2006). Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol, 7, 556-64. DOI ScienceOn |
12 | Liu XH, Rose DP (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res, 56, 5125-7. |
13 | Mittal A, Poudel B, Pandeya DR, et al (2012). Serum amyloid a as an independent prognostic factor for renal cell carcinoma--a hospital based study from the Western region of Nepal. Asian Pac J Cancer Prev, 13, 2253-5. 과학기술학회마을 DOI ScienceOn |
14 | Motzer RJ, Bander NH, Nanus DM (1996). Renal-cell carcinoma. N Engl J Med, 335, 865-75. DOI ScienceOn |
15 | Nogueira M, Kim HL (2008). Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol, 26, 113-24. DOI ScienceOn |
16 | Patel C, Ahmed A, Ellsworth P (2012). Renal cell carcinoma: a reappraisal. Urol Nurs, 32, 182-90; quiz 91. |
17 | Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res, 57, 1276-80. |
18 | Saussez S, Cucu DR, Decaestecker C, et al (2006). Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol, 13, 999-1009. DOI |
19 | Schmittgen TD, Livak KJ (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 3, 1101-8. DOI ScienceOn |
20 | Sejima T,Miyagawa I (2006). Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int J Urol, 13, 257-64. DOI ScienceOn |
21 | Shindo T, Masumori N, Kobayashi K, et al (2013). Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable. BJU Int, 111, 941-5. DOI ScienceOn |
22 | Shvarts O, Seligson D, Lam J, et al (2005). p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol, 173, 725-8. DOI ScienceOn |
23 | Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
24 | Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971). Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 28, 1165-77. DOI ScienceOn |
25 | Skolarikos A, Alivizatos G, Bamias A, et al (2005). Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int J Urol, 12, 563-9. DOI ScienceOn |
26 | Tatokoro M, Fujii Y, Kawakami S, et al (2011). Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci, 102, 137-43. DOI ScienceOn |
27 | Tostain J, Li G, Gentil-Perret A,Gigante M (2010). Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer, 46, 3141-8. DOI ScienceOn |
28 | Tsuchiya A, Sakamoto M, Yasuda J, et al (2003). Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol, 163, 2503-12. DOI ScienceOn |
29 | Wood CG (2006). Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol, 94, 264-5. DOI ScienceOn |
30 | Wei C, Lai YQ, Li XX,Ye JX (2013a). TGF-beta-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 315-20. 과학기술학회마을 DOI ScienceOn |